<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYDROCHLOROTHIAZIDE <img border="0" src="../images/pr.gif"/></span><br/>(hye-droe-klor-oh-thye'a-zide)<br/><span class="topboxtradename">Apo-Hydro <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Diaqua, </span><span class="topboxtradename">Esidrix, </span><span class="topboxtradename">Hydro-Chlor, </span><span class="topboxtradename">HydroDIURIL, </span><span class="topboxtradename">Hydromal, </span><span class="topboxtradename">Hydro-T, </span><span class="topboxtradename">Oretic, </span><span class="topboxtradename">SK-Hydrochlorothiazide, </span><span class="topboxtradename">HCTZ, </span><span class="topboxtradename">Urozide <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">electrolytic and water balance agent</span>; <span class="classification">diuretic</span>; <span class="classification">thiazide</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>12.5 mg capsules; 25 mg, 50 mg, 100 mg tablets; 50 mg/5 mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Similar to chlorothiazide. Diuretic action is associated with drug interference with absorption of sodium ions across the
         distal renal tubular segment of the nephron. This enhances excretion of sodium, chloride, potassium, bicarbonates, and water.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It has hypotensive action, elevates plasma renin activity, and precipitates diabetes in the prediabetic patient.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct in treatment of edema associated with CHF, hepatic cirrhosis, renal failure, and in the stepped-care management of
         hypertension (step 1 and 2 agent).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Nephrogenic diabetes insipidus, hypercalciuria, and treatment of electrolyte disturbances associated with renal tubular acidosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to thiazides or other sulfonamides; anuria, pregnancy (category B), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bronchial asthma, allergy; hepatic cirrhosis; renal dysfunction; history of gout, SLE; diabetes mellitus; older adults.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Edema</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 25200 mg/d in 13 divided doses<br/><br/><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12.5100 mg/d in 12 divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 2.2 mg/kg/d in 2 divided doses<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO</span> 6 mo, 24 mg/kg/d in 2 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk to reduce GI upset.</li>
<li>Schedule doses to avoid nocturia and interrupted sleep. If given in 2 doses, schedule second dose no later than 3 p.m.</li>
<li>Store tablets in tightly closed container at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Mood changes, unusual tiredness or weakness, dizziness, light-headedness, paresthesias. <span class="typehead">CV:</span> Irregular heartbeat, weak pulse, orthostatic hypotension. <span class="typehead">GI:</span> Dry mouth, increased thirst, nausea, vomiting, anorexia, diarrhea, pancreatitis, jaundice. <span class="typehead">Hematologic:</span> <span class="speceff-life">Agranulocytosis</span>, thrombocytopenia, <span class="speceff-life">aplastic anemia</span>, leukopenia. <span class="typehead">Metabolic:</span> <span class="speceff-common">Hyperglycemia,</span> glycosuria, <span class="speceff-common">hyperuricemia, hypokalemia</span>. <span class="typehead">Other:</span> Hypersensitivity reactions, photosensitivity, blurred vision, yellow vision (xanthopsia), muscle spasm. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Falsely decreased value in <span class="alt">total-urinary estrogen</span> by <span class="alt">spectrophotometric assay.</span> See <span class="alt">chlorothiazide.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Amphotericin B,</b> <span class="classification">corticosteroids</span> increase hypokalemic effects; <span class="classification">sulfonylureas</span>, <b>insulin</b> may antagonize hypoglycemic effects; <b>cholestyramine,</b> <b>colestipol</b> decrease <span class="classification">thiazide</span> absorption; <b>diazoxide</b> intensifies hypoglycemic and hypotensive effects; increased <b>potassium</b> and <b>magnesium</b> loss may cause <b>digoxin</b> toxicity; decreases <b>lithium</b> excretion and increases toxicity; increases risk of <span class="classification">nsaid</span>-induced renal failure and may attenuate diuresis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed. <span class="typehead">Onset:</span> 2 h. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Duration:</span> 612 h. <span class="typehead">Distribution:</span> Distributed throughout extracellular tissue; concentrates in kidney; crosses placenta; distributed in breast milk. <span class="typehead">Metabolism:</span> Does not appear to be metabolized. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 45120 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness. Antihypertensive effects may be noted in 34 d; maximal effects may require 34
            wk.
         </li>
<li>Lab tests: Baseline and periodic determinations of serum electrolytes, blood counts, BUN, blood glucose, uric acid, CO<sub>2</sub>, are recommended.
         </li>
<li>Check BP before initiation of therapy and at regular intervals.</li>
<li>Monitor closely for hypokalemia; it increases the risk of digoxin toxicity.</li>
<li>Monitor I&amp;O and check for edema.</li>
<li> 							Note: Drug may cause hyperglycemia and loss of glycemic control in diabetics. 						</li>
<li> 							Note: Drug may cause orthostatic hypotension, dizziness. 						</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Consult physician before using OTC drugs. Many contain large amounts of sodium as well as potassium.</li>
<li>Monitor weight daily.</li>
<li> 							Note: Diabetic patients need to monitor blood glucose closely. This drug causes impaired glucose tolerance. 						</li>
<li>Report signs of hypokalemia (see Appendix F) to physician.</li>
<li>Change positions slowly; avoid hot baths or showers, extended exposure to sunlight, and sitting or standing still for long
            periods.
         </li>
<li> 							Note: Photosensitivity reaction may occur 1014 d after initial sun exposure. 						</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>